Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2005;96:1185-1192
Published online before print May 19, 2005, doi: 10.1161/01.RES.0000170229.49776.81
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v97,pe6)
Right arrow All Versions of this Article:
96/11/1185    most recent
01.RES.0000170229.49776.81v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamakuchi, M.
Right arrow Articles by Lowenstein, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamakuchi, M.
Right arrow Articles by Lowenstein, C. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Attack
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Animal models of human disease
Right arrow Pathophysiology
Right arrow Ischemic biology - basic studies
(Circulation Research. 2005;96:1185.)
© 2005 American Heart Association, Inc.


Integrative Physiology

HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size

Munekazu Yamakuchi, James J.M. Greer, Scott J. Cameron, Kenji Matsushita, Craig N. Morrell, Karen Talbot-Fox, William M. Baldwin, III, David J. Lefer, Charles J. Lowenstein

From the Departments of Medicine (M.Y., K.M., C.J.L.), Pathology (S.J.C., C.N.M., K.T.-F., W.M.B. III, C.J.L.), and Comparative Medicine (C.N.M.), The Johns Hopkins University School of Medicine, Baltimore, Md; Departments of Physiology and Medicine (J.J.M.G., D.J.L.), Louisiana State University, Shreveport, La.

Correspondence to Charles J. Lowenstein, 950 Ross Bldg., 720 Rutland Ave., The Johns Hopkins University School of Medicine, Baltimore, MD, 21205. E-mail clowenst{at}jhmi.edu

Three-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors protect the vasculature from inflammation and atherosclerosis by cholesterol dependent and cholesterol independent mechanisms. We hypothesized that HMG-CoA reductase inhibitors decrease exocytosis of Weibel-Palade bodies, endothelial cell granules whose contents promote thrombosis and vascular inflammation. We pretreated human aortic endothelial cells with simvastatin for 24 hours, then stimulated the cells with thrombin, and measured the amount of vWF released into the media. We then measured the effect of simvastatin on myocardial infarction in mice. Simvastatin decreased thrombin-stimulated Weibel-Palade body exocytosis by 89%. Simvastatin inhibited exocytosis in part by increasing synthesis of nitric oxide (NO), which S-nitrosylated N-ethylmaleimide sensitive factor (NSF), a critical regulator of exocytosis. Simvastatin treatment attenuated myocardial infarct size by 58% in wild-type but not eNOS knockout mice. Furthermore, simvastatin decreased endothelial exocytosis and neutrophil infiltration into ischemic-reperfused myocardium, which was mediated in part by P-selectin contained in Weibel-Palade bodies. However, simvastatin did not affect exocytosis and inflammation in myocardial infarcts of eNOS knockout mice. Inhibition of endothelial exocytosis is a novel mechanism by which HMG-CoA reductase inhibitors may reduce vascular inflammation, inhibit thrombosis, and protect the ischemic myocardium. These findings may explain part of the pleiotropic effects of statin therapy for patients with cardiovascular disease.


Key Words: endothelium • nitric oxide • myocardial infarction • hypercholesterolemia




This article has been cited by other articles:


Home page
Vet PatholHome page
A. Ramachandran, S. Jha, and D. J. Lefer
REVIEW Paper: Pathophysiology of Myocardial Reperfusion Injury: The Role of Genetically Engineered Mouse Models
Vet. Pathol., September 1, 2008; 45(5): 698 - 706.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ye, J. D. Martinez, R. J. Perez-Polo, Y. Lin, B. F. Uretsky, and Y. Birnbaum
The role of eNOS, iNOS, and NF-{kappa}B in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H343 - H351.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
U. M. Breland, B. Halvorsen, J. Hol, E. Oie, G. Paulsson-Berne, A. Yndestad, C. Smith, K. Otterdal, U. Hedin, T. Waehre, et al.
A Potential Role of the CXC Chemokine GRO{alpha} in Atherosclerosis and Plaque Destabilization: Downregulatory Effects of Statins
Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 1005 - 1011.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Yagi, K.-i. Aihara, Y. Ikeda, Y. Sumitomo, S. Yoshida, T. Ise, T. Iwase, K. Ishikawa, H. Azuma, M. Akaike, et al.
Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency
Circ. Res., January 4, 2008; 102(1): 68 - 76.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. W. Calvert, S. Gundewar, M. Yamakuchi, P. C. Park, W. M. Baldwin III, D. J. Lefer, and C. J. Lowenstein
Inhibition of N-Ethylmaleimide Sensitive Factor Protects Against Myocardial Ischemia/Reperfusion Injury
Circ. Res., December 7, 2007; 101(12): 1247 - 1254.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Merla, Y. Ye, Y. Lin, S. Manickavasagam, M.-H. Huang, R. J. Perez-Polo, B. F. Uretsky, and Y. Birnbaum
The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1918 - H1928.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J. Afilalo, A. A Majdan, and M. J Eisenberg
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Heart, August 1, 2007; 93(8): 914 - 921.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ye, Y. Lin, R. Perez-Polo, M.-H. Huang, M. G. Hughes, D. J. McAdoo, S. Manickavasagam, B. F. Uretsky, and Y. Birnbaum
Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H813 - H818.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. G. Rondaij, R. Bierings, A. Kragt, J. A. van Mourik, and J. Voorberg
Dynamics and Plasticity of Weibel-Palade Bodies in Endothelial Cells
Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1002 - 1007.
[Abstract] [Full Text] [PDF]